-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Isentress
August 2012 Safety Labeling Changes
Translation The MedWatch August 2012 Safety Labeling Changes posting includes 53 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. The “Summary Page” provides a listing of drug names … Continue reading
Posted in FDA 2012, FDA Label Change
Tagged and Lamictal XR, and Mirapex ER, Aplenzin, Artemether/Lumefantrine, atomoxetine hydrochloride, Atrovent HFA, August 2012, August 2012 Safety Labeling Changes, Avelox, Bactrim, Bactrim DS, Bupropion Hydrobromide, Capoten, Captopril, Cladribine, Coartem, Complera, Cyclosporine, Diovan HCT, Disoproxil Fumarate, drug risks, Drug Safety Communication, Edurant, efavirenz, Emtricitabine, Enfuvirtide, Etravirine, Fesoterodine Fumarate, Fuzeon, Intelence, Invega Sustenna, Ipratropium Bromide HFA, Isentress, Lamictal, Lamotrigine, Leustatin, Linagliptin, Lovaza, Lucentis, Maraviroc, Mirapex, Moviprep, Moxifloxacin Hydrochloride, Neoral oral Solution, Neoral Soft Gelatin, Nexavar, Norelgestromin/Ethinyl Estradiol, Omega-3-Acid Ethyl Esters, Optison, Ortho Evra, Oxaliplatin, Paliperidone Palmitrate, Panitumumab, PEG-3350, Perflutren Protein-Type A Microspheres Injectable Suspension, Potassium Chloride, pramipexole dihydrochloride, Raltegravir, Ranibizumab, Revatio, Rilpivirine, safety label changes, Safety Labeling Changes, Sanctura XR, Sandimmune, Selzentry, Sevoflurane, sildenafil, Sodium Ascorbate and Ascorbic Acid, Sodium Chloride, Sodium Sulfate, Sorafenib, Spectinomycin, Strattera, Sulfamethoxazole and Trimethoprim, Sustiva, Tenofovir Diovan, Tenofovir Disoproxil Fumarate, Toviaz, Tradjenta, Trobicin, trospium chloride, Ultane and Ultane NovaPlus, USP), valsartan, valsartan/hydrochlorothiazide, Vectibix, Viread
Comments Off
December 2011 Safety Labeling Change
TranslationThe MedWatch December 2011 Safety Labeling Changes posting includes 40 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. The “Summary Page” provides a listing of drug names and … Continue reading
Posted in FDA 2011, FDA Label Change, FDA Warning
Tagged Capoten, Danocrine, December 2011, December 2011 Safety Labeling Change, Desferal, Dilantin-125, drugs, Edarbi, Eloxatin, fda, Heparin, Isentress, Keppra, labeling change, Multaq tablets, Norvir, notice, Onglyza, Ovide, PegIntron, Plavix, Relenza, Remeron, safety, Tyzeka, warnings, Zegerid
Comments Off